Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease

Movement Disorders

Volumn 25, Issue 3, 2010, Pages 332-340

  Lee, Seung Hun ^a   Kim, Mi Jung ^a   Kim, Beom Jun ^a   Kim, Sung Reul ^a   Chun, Sail ^a   Ryu, Jin Sook ^a   Kim, Ghi Su ^a   Lee, Myoung Chong ^a   Koh, Jung Min ^a   Chung, Sun Ju ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Folate; Homocysteine; Osteoporosis; Parkinson's disease; Vitamin B12

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CYANOCOBALAMIN; FOLDA; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; LIPO A HR; MECOBALAMIN; PARATHYROID HORMONE; PHOSPHORUS; THIOCTIC ACID; UNCLASSIFIED DRUG;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPIGASTRIC PAIN; FEMALE; FEMUR; FEMUR SHAFT; FRACTURE; GREATER TROCHANTER; HUMAN; KOREA; LESSER TROCHANTER; LUMBAR SPINE; MALE; NAUSEA; OPEN STUDY; OSTEOLYSIS; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PARKINSON DISEASE; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VERTEBRA DISLOCATION; VITAMIN BLOOD LEVEL; WRIST FRACTURE;

ABSORPTIOMETRY, PHOTON; AGED; ANALYSIS OF VARIANCE; ANTHROPOMETRY; ANTIOXIDANTS; BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; COLLAGEN TYPE I; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDES; THIOCTIC ACID;

EID: 77649158888     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22866     Document Type: Article

References (41)

1. Genever RW, Downes TW, Medcalf P. Fracture rates in Parkinson's disease compared with age and gender-matched controls: a retrospective cohort study. Age Ageing 2005;34:21-24.
2. Johnell O, Melton LJ, III, Atkinson EJ, O'Fallon WM, Kurland LT. Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 1992; 21:32-38.
3. Taylor BC, Schreiner PJ, Stone KL, et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 2004;52:1479-1486.
4. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001;182:89-93.
5. Vaserman N. Parkinson's disease and osteoporosis. Joint Bone Spine 2005;72:484-488.
6. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997;49:1273-1278.
7. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:64-68.
8. Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH. Bone mineral density in patients with Parkinson's disease measured by dual photon absorptiometry. Nucl Med Commun 1994;15:173-177.
9. Taggart H, Crawford V. Reduced bone density of the hip in elderly patients with Parkinson's disease. Age Ageing 1995;24: 326-328.
10. Blandini F, Fancellu R, Martignoni E, et al. Plasma homocysteine and L-dopa metabolism in patients with Parkinson disease. Clin Chem 2001;47:1102-1104.
11. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003;60: 1125-1129.
12. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Jr, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004;19: 1403-1408.
13. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003;108:66-67.
14. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60:59-64.
15. Gjesdal CG, Vollset SE, Ueland PM, et al. Plasma total homocysteine level and bone mineral density: the Hordaland homocysteine study. Arch Intern Med 2006;166:88-94.
16. Golbahar J, Hamidi A, Aminzadeh MA, Omrani GR. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study. Bone 2004;35:760-765.
17. Morris MS, Jacques PF, Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005;37:234-242.
18. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042-2049.
19. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in stroke patients. Bone 2005;36:721-726.
20. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-2041.
21. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W. Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem 2005;51: 2348-2353.
22. Koh JM, Lee YS, Kim YS, et al. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res 2006;21:1003-1011.
23. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005;293:1082-1088.
24. Koh JM, Lee YS, Byun CH, et al. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. J Endocrinol 2005;185:401-413.
25. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
26. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washsington DC: National Osteoporosis Foundation, 2003.
27. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol 2004;3:173-189.
28. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
29. Fahn S, Elton R,Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease, Vol.2. Florham Park, NJ: Macmillan Health Care Information, 1987. p 153-163, 293-304.
30. Kiel D. Assessing vertebral fractures. National osteoporosis foundation working group on vertebral fractures. J Bone Miner Res 1995;10:518-523.
31. Omsland TK, Schei B, Grønskag AB, et al. Weight loss and distal forearm fractures in postmenopausal women: the Nord-Trøndelag health study, Norway. Osteoporos Int 2009 (in press). 32. Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007;68:911-915.
32. Sato Y, Iwamoto J, Kanoko T, Satoh K. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord 2006;21:924-929.
33. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996;1315:159-162.
34. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005;118:1250-1255.
35. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int 2007;81:153-161.
36. Nakaso K, Yasui K, Kowa H, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-dopa, homocysteine, and MTHFR genotype. J Neurol Sci 2003;207:19-23.
37. Ozer F, Meral H, Hanoglu L, et al. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 2006;28:853-858.
38. Zoccolella S, Dell'aquila C, Abruzzese G, et al. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov Disord 2009;24:1028-1033.
39. Kim MS, Park JY, Namkoong C, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004;10:727-733.
40. Roux C, Garnero P, Thomas T, Sabatier J, Orcel P, Audran M. Recommendations for monitoring antiresorptive therapies in post-menopausal osteoporosis. Joint Bone Spine 2005;72:26-31.
41. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004;63:886-891.